Collagen Corp.
This article was originally published in The Gray Sheet
Executive Summary
Establishes shareholder rights plan "intended to provide protection to...stockholders from abusive and coercive tactics that are often prevalent in attempted takeovers," the company states. The plan is not designed to "prevent a fair acquisition," Collagen says, adding that it is not aware of any acquisition proposals. The plan was adopted in response to the recent increase in health care industry takeovers, the company explains. The rights will be distributed to shareholders of record on Dec. 14, and will become exercisable 10 days after a person or group acquires 20% or more of the firm's stock. Collagen also reports that it has completed its latest stock repurchase effort, re-acquiring 300,000 additional shares "in the open market." The company has repurchased about 1.2 mil. shares at an average price of $22.50 per share since the inception of its repurchase program in February 1993
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.